Ilofotase alfa for the prevention of kidney damage after heart surgery
Résumé de l'étude
This study is aimed at patients scheduled for open-heart surgery. Up to 30% of all patients undergoing open-heart surgery develop kidney damage after the operation, for which there is currently no specific treatment. Ilofotase alfa is a new drug that mimics the protein alkaline phosphatase found in many human tissues. The aim of this study is to find out how well Ilofotase alfa is tolerated and whether it effectively reduces the risk of kidney damage after surgery; the safety of the treatment will also be investigated. Ilofotase alfa is still under development and is not yet approved for treatment. Study participants will receive, in addition to their standard treatment, either two doses of Ilofotase alfa or two doses of placebo as an infusion (the placebo contains no active ingredient). Neither the patient nor the investigator knows whether the patient receives Ilofotase alfa or placebo (double-blind study). Participation in the study lasts about 3 months and includes 9 study visits. At least 6 of these visits occur while the patient is hospitalized for open-heart surgery. During the study visits, blood tests (at 8 visits), urine analyses (at 6 visits), and an electrocardiogram (at 1 visit) will be performed.
(BASEC)
Intervention étudiée
Study participants will receive on the day of their heart surgery either two doses of the study drug Ilofotase alfa, or two doses of placebo (control, contains no active ingredient). The first dose is given before the surgery, the second after.
(BASEC)
Maladie en cours d'investigation
Risk of kidney damage after open-heart surgery
(BASEC)
- At least 18 years old - Scheduled open-heart surgery using a heart-lung machine; certain types of bypass and/or heart valve surgeries are eligible - Kidney function must be within certain limits before surgery (BASEC)
Critères d'exclusion
- Less than 55 kg body weight - Known or suspected inflammation of the filtering cells in the renal glomeruli or inflammation of the blood vessel walls - Confirmed or treated inflammation of the endocardium that required treatment for bacteria, protozoa, fungi, or viruses within the last 30 days prior to surgery, or any other active inflammation within the last 14 days prior to surgery that required such treatment. (BASEC)
Lieu de l’étude
Berne, Lausanne
(BASEC)
Sponsor
AM-Pharma B.V. FGK Representative Service AG
(BASEC)
Contact pour plus d'informations sur l'étude
Personne de contact en Suisse
Thomas Hanke
+41 43 508 3632
thomas.hanke@clutterfgk-rs.comFGK Representative Service AG
(BASEC)
Informations scientifiques
non disponible
Nom du comité d'éthique approbateur (pour les études multicentriques, uniquement le comité principal)
Commission cantonale d'éthique de Berne
(BASEC)
Date d'approbation du comité d'éthique
05.11.2024
(BASEC)
Identifiant de l'essai ICTRP
non disponible
Titre officiel (approuvé par le comité d'éthique)
Double-blind, Randomized, Placebo-controlled Trial to Evaluate the Efficacy and Safety of Ilofotase Alfa in Patients at Risk for Renal Damage Following Open Heart Surgery (BASEC)
Titre académique
non disponible
Titre public
non disponible
Maladie en cours d'investigation
non disponible
Intervention étudiée
non disponible
Type d'essai
non disponible
Plan de l'étude
non disponible
Critères d'inclusion/exclusion
non disponible
non disponible
Critères d'évaluation principaux et secondaires
non disponible
non disponible
Date d'enregistrement
non disponible
Inclusion du premier participant
non disponible
Sponsors secondaires
non disponible
Contacts supplémentaires
non disponible
ID secondaires
non disponible
Résultats-Données individuelles des participants
non disponible
Informations complémentaires sur l'essai
non disponible
Résultats de l'essai
Résumé des résultats
non disponible
Lien vers les résultats dans le registre primaire
non disponible